CN101032494A - Application of Asiatic Acid in the preparing of medicine for preventing and curing kidney fibrosis - Google Patents
Application of Asiatic Acid in the preparing of medicine for preventing and curing kidney fibrosis Download PDFInfo
- Publication number
- CN101032494A CN101032494A CN 200610024408 CN200610024408A CN101032494A CN 101032494 A CN101032494 A CN 101032494A CN 200610024408 CN200610024408 CN 200610024408 CN 200610024408 A CN200610024408 A CN 200610024408A CN 101032494 A CN101032494 A CN 101032494A
- Authority
- CN
- China
- Prior art keywords
- uuo
- group
- kidney
- asiatic acid
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 11
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 title claims abstract 7
- 229940011658 asiatic acid Drugs 0.000 title claims abstract 7
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 title claims abstract 7
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 title claims abstract 7
- 206010023421 Kidney fibrosis Diseases 0.000 title 1
- 201000002793 renal fibrosis Diseases 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 210000003734 kidney Anatomy 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 15
- 206010016654 Fibrosis Diseases 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 6
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 6
- 229940022757 asiaticoside Drugs 0.000 description 6
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 206010046555 Urinary retention Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108010074496 rat smooth muscle actin Proteins 0.000 description 2
- 238000012764 semi-quantitative analysis Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了积雪酸在制备预防或治疗肾脏纤维化的药物中的应用。本发明通过用积雪酸对大鼠肾脏纤维化的影响，证实了积雪酸具有抗肾脏纤维化的作用。因而，积雪酸可作为活性成份用于制备抗肾脏纤维化的药物。The invention discloses the application of asiatic acid in the preparation of medicines for preventing or treating renal fibrosis. The present invention confirms that asiatic acid has the effect of resisting renal fibrosis through the influence of asiatic acid on rat renal fibrosis. Therefore, asiatic acid can be used as an active ingredient in the preparation of drugs against renal fibrosis.
Description
Technical field
The present invention relates to the application of accumulated snow acid in pharmacy, relate in particular to the application of accumulated snow acid in the medicine of preparation prevention or treatment renal fibrosis.
Background technology
Herba Centellae is a kind of plant amedica, and asiaticoside is the material that extracts from Herba Centellae, is also referred to as asiaticoside (Asiaticoside), and structure is seen formula II.
Discover asiaticoside behind the treatment mucocutaneous injury, it has the effect of fiber cicatrix hyper-proliferative.This material all has listing as the cosmetics and the medicine of associated uses, and asiaticoside is its main active ingredient in these products.Accumulated snow acid is the aglycon that promptly forms after the asiaticoside desaccharide, and its structure is seen shown in the formula I:
Formula I
Summary of the invention
The purpose of this invention is to provide the application of accumulated snow acid in the medicine of preparation prevention or treatment renal fibrosis.
Wherein, described kidney can be matter and/or glomerule between kidney, matter between preferred kidney.
Inquire into the protective effect of accumulated snow acid (JXS) to unilateral ureteral occlusion (UUO) (UUO) kidney of rats interstitial fibrosis.Method: rat is divided into UUO group and UUO+JXS group at random, and other establishes sham-operation (SHAM) group.Medication group (being the UUO+JXS group) Rhizoma Atractylodis Macrocephalae first three day filling stomach gives accumulated snow acid 20mg/kg, matched group (being the SHAM group) and UUO group give the equal-volume normal saline, put to death animal on the 21st day until postoperative, observe the left kidney pathological change, relatively matter matrix content and kidney region fibrosis degree between kidney; With α-smooth muscle actin (immunohistochemical observation renal cells situation transition of α-SMA).
Positive progressive effect of the present invention is: the present invention has confirmed that by using accumulated snow acid to the Fibrotic influence of rat kidney accumulated snow acid has the effect of anti-renal fibrosis.Thereby accumulated snow acid can be used as the medicine that active ingredient is used to prepare anti-renal fibrosis.
The specific embodiment
Embodiment 1
1. materials and methods
1.1 laboratory animal wistar rat (Chinese Academy of Sciences's Shanghai Experimental Animal Center) is male, healthy cleaning level, and in 8 ages in week, body weight 180～220g, feeding environment are 5 in every cage, 22 ± 2 ℃ of room temperatures, relative humidity 55 ± 2%.
1.2 medicine and the acid of reagent accumulated snow are made by Guangxi Chang Zhou natural product development corporation, Ltd. or Shanghai Institute of Pharmaceutical Industry, (antibody of α-SMA) is available from SIGMA company for mouse anti rat α-smooth muscle actin, the anti-mice IgG of rabbit instant two is anti-available from last hai antibody company, and DBA colour reagent box is available from magnificent company.
1.3 method
1.3.1 rat was fixed with the right clinostatism in 10% chloral hydrate 0.03ml/kg IP anesthesia back when animal model was made operation, the cropping sterilization, the left abdomen otch, separate the left side ureter, 5-0 silk thread ligation twice, last one ligation point is positioned at left inferior pole of kidney level, cuts off ureter between twice ligation point, and layer-by-layer suture is made the UUO model.Sham operated rats is only opened abdomen and free left side ureter, but not ligation and cutting off.
1.3.2 animal grouping and administration rat are divided into three groups at random, are respectively sham-operation (SHAM) group, UUO group and UUO+JXS group, at UUO art first three day beginning administration JXS 36mg/kg until UUO postoperative the 21st day.
1.3.3 the 21st day blood specimen of inspection item postoperative isolated serum and detected biochemical routine, puts to death animal, it is quantitative to extract UUO rats with left residual urine; Leave and take left kidney, nephridial tissue is divided 2 parts, and a part is made the light microscopic pathologic finding, and another part percutaneous, medullary substance separation are placed on-70 ℃ of frozen α of work-SMA SABC.The SHAM rat is left and taken left kidney and does same the processing.
1.3.4 tissue pathology checking's nephridial tissue is fixed through 4% paraformaldehyde buffer, PAS and MASSON dyeing is carried out in 3 μ m section after the paraffin embedding.Light microscopic is pathological changes such as matter cell infiltration degree and fibrosis between observation PAS stained cortex kidney down, and double blinding gives PAS dyeing kidney ID change score down, and standard is: 0 minute (the ID change accounts for matter total amount＜5%); 1 minute (the ID change accounts for a matter total amount 5%-15%); 2 minutes (the ID change accounts for a matter total amount 15%-30%); 3 minutes (the ID change accounts for a matter total amount 30%-60%); 4 minutes (the ID change accounts for matter total amount＞60% or focal necrosis is arranged).Every section is got 10 nonoverlapping visuals field under 200 times of situations of amplification, given a mark in each visual field respectively, averages as the ID change score of this specimen.Semi-quantitative analysis is carried out in section to MASSON dyeing nephridial tissue, concrete steps are as follows: adopt Beijing Institute of Aeronautics medical image analysis management system, under identical conditions, 15 of every specimen selection are not repeated the visual field (40 *), be considered as positive target with being rendered as green zone of fiber (removing glomerule and trunk), with the ratio of positive area and the statistics field gross area fibrosis index as matter between renal tubules.Adopting Beijing Institute of Aeronautics medical image acquisition and analytical system software that MASSON is dyeed analyzes.
1.3.5 α-conventional dewaxing of SMA SABC section is immersed 37 ℃ and is contained 1.5%H to anhydrous
2O
2Methanol 30min eliminate the endogenous peroxidase, trypsinization exposes antigen site, an anti-(mouse anti rat α-SMA antibody, 1: 200) 4 ℃ spend the night, then place 30min for 37 ℃ with corresponding instant two anti-(the anti-mice IgG of rabbit, 1: 200), develop the color with DAB at microscopically at last.The method that adopts the deletion first antibody simultaneously is as negative control.(400 *) adopt Beijing Institute of Aeronautics medical image analysis management system to carry out semi-quantitative analysis to 15 nonoverlapping visuals field of every section picked at random under high power lens, and the result represents with the positive target gross area/statistics gross area.All data are represented with x ± s, utilize SPSS10.0 software to carry out statistical analysis, adopt one factor analysis of variance and SNK check respectively to organize difference.
2. result:
2.1 the experimental rat base values is observed UUO rats with left renal pelvis and dilatation of ureter, interiorly is the residual urine after blocking.UUO group and UUO+JXS group residual urine volume there was no significant difference, each treated animal serum biochemistry index is normally, compares there was no significant difference between group, sees Table 1.
Table 1 UUO rat model base values (n=6)
| Group | ?Triglyceride ? ?mmol.L -1 | ?Cholesterol ? ?mmol.L -1 | ?Glucose ? ?mmol.L -1 | ?BUN ? ?mmol.L -1 | ?Creatinine ? ?μmol.L -1 | ?Resudual ? ?Urine/ml |
| ?SHAM ?UUO ?UUO+JXS | ?0.92±0.49 ?0.89±0.36 ?0.91±0.78 | ?2.01±0.45 ?1.93±0.28 ?1.82±0.33 | ?6.39±2.03 ?5.86±1.88 ?6.58±1.45 | ?6.32±1.42 ?7.17±2.25 ?5.65±1.08 | ?29.65±5.32 ?36.30±6.21 ?34.58±7.20 | ?0 ?3.86±0.40 ?3.52±0.32 |
Triglyceride: triglyceride; Cholesterol: cholesterol; Glucose: glucose; BUN: serum urea nitrogen; Creatinine: creatinine; Resudual Urine residual urine volume.
2.2 the pathological change of rat left side nephridial tissue
2.2.1PAS dyeing is compared with SHAM group rat, matter broadening between 21 days nephridial tissues has more inflammatory cell infiltration behind the UUO, tubular ectasia, and accidental urinary cast intracavity has neutrophil accumulation, and visible renal cells atrophy, necrosis, comes off; UUO+JXS organizes above-mentioned change and obviously alleviates, and each is organized kidney ID change score and the results are shown in Table 2.
Table 2 kidney of rats histopathology, SABC result (n=6)
| Group | Damage?score | ?Interstitial?fibrosis?index | ?α-SMA?Positive?area/％ |
| ?SHAM ?UUO ?UUO+JXS | 0 2.198±0.760 a1.326±0.586 ab | ?0.021±0.004 ?0.087±0.203 a?0.042±0.147 b | ?0.003±0.001 ?0.132±0.058 a?0.021±0.123 ab |
Compare with the SHAM group,
aP＜0.05; Compare with the UUO group,
bP＜0.05
Damage score: damage umber; Interstitial fibrosis index: interstitial fibrosis index; The positive area of α-SMA Positive area: α-SMA.
2.2.2 having a small amount of green, the visible glomerular basement membrane of MASSON dyeing SHAM group section dyes several no gaps between tubule.Matter broadening and extensive green between 21 days nephridial tissues behind the UUO show that matrix components increases, and fibrosis is obvious.UUO+JXS group kidney region fibrosis index obviously alleviates, and the results are shown in Table 2.
2.3 left kidney α-SMA SABC detects SHAM group rat α-SMA and only is expressed in renal blood vessels smooth muscle and tunica adventitia confluent monolayer cells, does not almost have expression at a renal tubules and a matter.UUO group renal cortex α-SMA dyeing obviously increases, mainly be positioned at marrow, cortex renal cells and broadening kidney between the matter district α-SMA positive expression also appears, the prompting renal cells to the muscle fiber cell transition, a matter fibroblast showed increased.The expression of the UUO+JXS group α-SMA of cortical areas significantly reduces, and sees Table 2.
Conclusion: compare with the UUO group, the pathological change and the kidney region fibrosis degree of UUO+JXS group left kidney obviously alleviate (p＜0.05), the expression of renal cells α-SMA obviously reduces (p＜0.05), and the SHAM group does not have obvious influence to the left kidney pathology.Accumulated snow acid has protective effect to the kidney of rats interstitial fibrosis due to the UUO, and its mechanism may partly be by reducing renal cells to the transition of muscle fiber cell, thereby improves kidney region fibrosis.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610024408 CN101032494A (en) | 2006-03-06 | 2006-03-06 | Application of Asiatic Acid in the preparing of medicine for preventing and curing kidney fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610024408 CN101032494A (en) | 2006-03-06 | 2006-03-06 | Application of Asiatic Acid in the preparing of medicine for preventing and curing kidney fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105835381A Division CN102000088A (en) | 2006-03-06 | 2006-03-06 | Application of snow acid in preparation of medicament for preventing or treating kidney fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101032494A true CN101032494A (en) | 2007-09-12 |
Family
ID=38729360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610024408 Pending CN101032494A (en) | 2006-03-06 | 2006-03-06 | Application of Asiatic Acid in the preparing of medicine for preventing and curing kidney fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101032494A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2231139B1 (en) * | 2008-01-11 | 2015-02-25 | Shanghai Institute of Pharmaceutical Industry | Therapeutic formulations based on asiatic acid and selected salts thereof |
-
2006
- 2006-03-06 CN CN 200610024408 patent/CN101032494A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2231139B1 (en) * | 2008-01-11 | 2015-02-25 | Shanghai Institute of Pharmaceutical Industry | Therapeutic formulations based on asiatic acid and selected salts thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112691114B (en) | Application of momordica polysaccharide in preparation of medicine for treating ulcerative colitis and pharmaceutical preparation of momordica polysaccharide | |
| Biswas et al. | CHEMOPREVENTIVE ACTIVITY OF THE ETHANOLIC EXTRACT OF ASTRAEUS HYGROMETRICUS (PERS.) MORG. ON EHRLICH'S ASCITES CARCINOMA CELLS. | |
| DE112011102350T5 (en) | A combination pharmaceutical composition and method for treating disorders of the genitourinary system | |
| Somchaichana et al. | Acanthus ebracteatus Vahl. Ethanol Extract Enhancement of the Efficacy of the Collagen Scaffold in Wound Closure: A Study in a Full‐Thickness‐Wound Mouse Model | |
| Abbasifard et al. | Topical bee venom nano-emulsion ameliorates serum level of endothelin-1 in collagen-induced rheumatoid arthritis model | |
| Zhang et al. | Effects of Morinda officinalis polysaccharide on experimental varicocele rats | |
| Bae et al. | Reduction of oxidative stress may play a role in the anti‐inflammatory effect of the novel herbal formulation in a rat model of hydrochloric acid‐induced cystitis | |
| Taddese et al. | Wound healing activities of hydromethanolic crude extract and solvent fractions of bersama abyssinica leaves in mice | |
| KR102402139B1 (en) | Use of ginsenoside m1 for treating lupus nephritis | |
| Khalil et al. | Emerging approach for the application of Hibiscus sabdariffa extract ointment in the superficial burn care | |
| CN102698292A (en) | Preparation method of animal model simulating human pelvic inflammatory disease (PID) | |
| CN101032494A (en) | Application of Asiatic Acid in the preparing of medicine for preventing and curing kidney fibrosis | |
| CN101032500A (en) | Application of centella triterpenes in the preparing of medicine for preventing and curing kidney fibrosis | |
| Alfiana et al. | The episiotomy effect of topical combination of cinnamon oil and red betel on skin wound healing mechanism | |
| CN102000088A (en) | Application of snow acid in preparation of medicament for preventing or treating kidney fibrosis | |
| Ozay et al. | Effects of methanolic extract of Verbascum inulifolium Hub.-Mor. on incisional and excisional skin wounds in diabetic and non-diabetic rats | |
| Ramos Melo et al. | Red propolis reduces inflammation in cyclophosphamide-induced hemorrhagic cystitis in rats | |
| Qin et al. | Studies on the protective effect of total flavonoids from Cichorium glandulosum roots against carbon tetrachloride-induced liver fibrosis in rats | |
| Akharaiyi et al. | Effect of Spathodea campanulata Ethanol Leaf Extract on Hematology and Liver Function of Salmonellainfected and Paracetamol-induced Swiss Albino Mice | |
| Căruntu et al. | Thuja occidentalis mother tincture alleviate the COX-2 expression in intestinal mucosa of the TNBS-induced ulcerative colitis model in mice | |
| Nailufar et al. | The evaluation of proton pump inhibitor bioactive fraction DLBS2411 from Cinnamomum burmannii (Nees & T. Nees) in animal model of gastric ulceration healing | |
| Hu et al. | Network pharmacology analysis uncovers the mechanism of Shudihuang-Shanzhuyu herb pair in prevention and treatment of diabetic osteoporosis via PI3K/AKT pathway | |
| Soji-Omoniwa et al. | Effect of co-administration of metformin and aqueous leaf extract of Bryophyllum pinnatum on kidney function indices in diabetic rats | |
| Wang et al. | Anti-rheumatic arthritis efficacy of Pueraria montana extract against type-II collagen-induced rheumatoid arthritis rat model an in vitro and in vivo assessment | |
| Pramono et al. | Comparative Effects of Yellow Root (Arcangelisia flava (L.) Merr.) Decoctions with Water and Brackish Water on Kidneys and Uterus in Wistar Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070912 |